Meridiano

Add Article

No Image Available

Article Details

Title

Article: China biotech outlicensing tops US$52 billion in first 2 months after global deal surge

Impact Score

5 / 10

AI Summary (Processed Content)

China's biotech sector saw outlicensing deals exceed $52 billion in total value in the first two months of 2024, surpassing any single quarter from the previous year.

This surge is exemplified by two major deals: Sino Biopharmaceutical's partnership with France's Sanofi and Antengene's agreement with Belgium's UCB, valued at up to $1.53 billion and $1.18 billion respectively.

The trend indicates China is becoming a key global source for innovative drug candidates, with multinational firms seeking long-term strategic partnerships over one-off transactions.

The main topics covered are the financial scale of China's biotech outlicensing, specific high-value deals with Western pharmaceutical companies, and the strategic shift towards sustained international partnerships.

Original URL

https://www.scmp.com/business/china-business/article/3345404/china-outlicensing-tops-us52-billion-first-two-months-rise-global-deals?utm_source=rss_feed

Source Feed

Tech - South China Morning Post

Published Date

2026-03-04 09:30

Fetched Date

2026-03-04 14:29

Processed Date

2026-03-04 15:28

Embedding Status

Present

Cluster ID

Not Clustered

Raw Extracted Content

China biotech outlicensing tops US$52 billion in first 2 months after global deal surge
The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB
The string of deals shows how China is becoming a sought-after source of drug candidates for multinational pharmaceutical companies, which are increasingly looking for long-term partnerships rather than one-off arrangements, analysts said.
The latest deals, Sino Biopharmaceutical’s agreement with France’s Sanofi worth up to US$1.53 billion and Antengene Corporation’s agreement with Belgium’s UCB valued at about US$1.18 billion, came as cross-border transactions by Chinese drug makers in the first two months of the year outpaced any single quarter last year in upfront payments and total value, according to Yang Huang, head of China healthcare research at JPMorgan Chase.
Hong Kong-listed Sino Biopharmaceutical said in an exchange filing on Wednesday that its Chia Tai Tianqing Pharmaceutical unit had granted a subsidiary of Sanofi the exclusive worldwide rights to develop, manufacture and sell rovadicitinib, an oral drug to treat blood cancer and immune-related diseases.